N@N

CryoLife (CRY) Gains As Much As 15.02% After BUYINS.NET Report Predicted On August 30th The Stock Would Rally On Seasonal Stren

^{Published on 2010-09-28 17:22:28, Last Modified on 2010-12-22 18:47:30 - WOPRAI}
 

September 28, 2010 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on August 30th, 2010 stating that CryoLife (NYSE: CRY) was expected to be higher due to seasonal strength in the stock. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?id=122281

The results of the prediction are the following:

Symbol 8/30/2010 Hi Since $Change % High 9/28/2010 $Change % Today

CRY $5.46 $6.28 $0.82 15.02% $6.07 $0.61 11.17%

By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

CryoLife, Inc. (NYSE: CRY) engages in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries in the United States and Canada. Its CryoValve SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. The companya�s CryoPatch SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract, a surgery commonly performed in children with congenital heart defects, such as tetralogy of Fallot, truncus arteriosus, and pulmonary atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch. CryoLifea�s BioGlue Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels. BioGlue is also CE Marked in the European community and approved in Canada and Australia for use in soft tissue repair. The companya�s BioFoam Surgical Matrix is CE Marked in the European community for use as an adjunct in the sealing of abdominal parenchymal tissues when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE Aesthetic Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty in reconstructive plastic surgery. CryoLife also distributes HemoStase, a hemostatic agent for use in cardiac and vascular surgery, as well as in various international markets for cardiac, vascular, and general surgery. The company distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. CryoLife was founded in 1984 and is headquartered in Kennesaw, Georgia.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net